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Abstract
Background: Drug-eluting bead transarterial chemoembolization (DEB-TACE) is a novel therapy for the
treatment of hypervascuarized tumours. Through the intra-arterial delivery of microspheres, DEB-TACE
allows for embolization as well as local release of chemotherapy in the treatment of hepatic malignancy,
providing an alternative therapeutic option in unresectable tumours. Its role as an adjunct to surgical
resection or radiofrequency ablation (RFA) is less clear. The purpose of this review is to summarize recent
studies investigating DEB-TACE in order to better define safety, efficacy and outcomes associated with
its use.
Methods: A systematic review of all published articles and trials identified nine clinical trials and 23
abstracts. These were reviewed for tumour histology, stage of treatment, delivery technique, outcome at
follow-up, complications and mortality rates.
Results: Publications involved treatment of hepatocellular carcinoma (HCC), metastatic colorectal car-
cinoma (MCRC), metastatic neuroendocrine (MNE) disease and cholangiocarcinoma (CCA). Using
Response Evaluation Criteria in Solid Tumours (RECIST) or European Association for the Study of the
Liver (EASL) criteria, studies treating HCC reported complete response (CR) rates of 5% (5/101) at 1
month, 9% (8/91) at 4 months, 14% (19/138) at 6 months and 25% (2/8) at 10 months. Partial response
(PR) was reported as 58% (76/131) at 1 month, 50% (67/119) at 4 months, 57% (62/108) at 6–7 months
and 63% (5/8) at 10 months. Studies involving MCRC, CCA and MNE disease were less valuable in terms
of response rate because there is a lack of comparative data. The most common procedure-associated
complications included fever (46–72%), nausea and vomiting (42–47%), abdominal pain (44–80%) and
liver abscess (2–3%). Rather than reporting individual symptoms, two studies reported rates of post-
embolic syndrome (PES), consisting of fever, abdominal pain, and nausea and vomiting, at 82% (75/91).
Six of eight studies reported length of hospital stay, which averaged 2.3 days per procedure. Mortality was
reported as occurring in 10 of 456 (2%) procedures, or 10 of 214 (5%) patients.
Conclusions: Drug-eluting bead TACE is becoming more widely utilized in primary and liver-dominant
metastatic disease of the liver. Outcomes of success must be expanded beyond response rates because
these are not a reliable surrogate for progression-free survival or overall survival. Ongoing clinical trials will
further clarify the optimal timing and strategy of this technology.
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Introduction
Primary hepatic carcinoma remains a relatively uncommon
disease in North America and Western Europe, representing 0.5–
2.0% of all cancers.1,2 However, it represents a much larger pro-
portion of malignancies (20–40%) in developing countries and is
the fifth or sixth most common malignancy worldwide, account-
ing for approximately 5.6% of all cancers.3,4 Hepatocellular carci-
noma (HCC) is the most common primary malignancy of the
liver (70–85%); an estimated 500 000 to one million new cases
occur annually and associated mortality amounts to approxi-
mately 600 000.3,5 Recent studies in the USA have shown that the
incidence of HCC is increasing, probably in relation to chronic
hepatitis C (HCV) infection.6 Other causes of primary liver cancer
are far less common and are led by cholangiocarcinoma (CCA),
which occurs in 5000–6000 patients per year.5
Despite recent increases in the incidence of HCC, metastatic
liver disease still represents the majority of malignant hepatic
neoplasms, with approximately 1.8 million cases per year.7
Metastases to the liver can potentially derive from malignancy at
any site in the body (including stomach, pancreas, biliary, renal,
prostate, neuroendocrine, breast, melanoma, retroperitoneal
sarcoma, ovarian, endometrial and cervix malignancies), as well as
leukaemias and lymphomas. Colorectal cancer is the most
common site of metastatic origin and the most relevant metastatic
liver tumour to the surgeon because of the potential for longterm
survival after complete resection of disease.8 For this reason, other
treatment modalities are being investigated for their roles in
enhancing the results of surgical resection in liver disease to
ensure the complete destruction of the tumour.9 These include
percutaneous ethanol injection (PEI), radiofrequency ablation
(RFA), transarterial chemoembolization (TACE) and, more
recently, drug-eluting bead transarterial chemoembolization
(DEB-TACE).
Drug-eluting bead TACE is a drug delivery system that com-
bines the local embolization of vasculature with the release of
chemotherapy into adjacent tissue.10,11 It is intended for use in the
treatment of hypervascular tumours such as HCC. Its administra-
tion is similar to that of conventional TACE and it represents a
minimally invasive procedure performed by interventional radi-
ologists.10,11 Beads are composed of biocompatible polymers such
as polyvinyl alcohol (PVA) hydrogel that has been sulphonated to
enable the binding of chemotherapy.12 The beads occlude vascu-
lature, causing embolization, and the chemotherapy is delivered
locally.13,14 In this paper we investigate the results of recent clinical
studies using DEB-TACE systems in the treatment of unresectable
primary and metastatic liver carcinoma.
Materials and methods
Literature review
Details on DC Bead™ products were obtained from a review of all
papers published in English-language peer review journals from
1995 to 2008. Unpublished studies and abstracts presented at
national and international meetings were included. Trials were
identified by conducting a comprehensive search of the
MEDLINE, EMBASE, Science Citation Index, Current Contents
and PubMed databases, using the medical subject headings ‘col-
orectal liver metastasis’, ‘hepatocellular carcinoma’, ‘chemoembo-
lization’, ‘transarterial chemoembolization’ and ‘DC Bead’. A
manual search of the abstracts was performed to identify papers
for inclusion in this review. Only articles that included an evalu-
ation of the DC Bead™ during this time period were included.
The outline of articles reviewed is presented in Fig. 1. The most
commonly treated tumours included HCC, liver metastases, CCA
and neuroendocrine cancer metastases. Eight clinical publications
from 2006 to 2009 exploring the safety and efficacy of DEB-TACE
(DC/LC Bead™; Biocompatibles UK Ltd, Farnham, UK) in the
treatment of hepatic malignancy were reviewed (Table 1).15–23
Additionally, 19 abstracts were reviewed, 17 of which provided
response rates, and all of which provided information on
procedure-related complications (Table 2). Unpublished abstracts
were presented between 2004 and 2008. Studies were evaluated
according to type of tumour histology, stage of disease, resectabil-
ity of malignancy, type of chemotherapy, DEB-TACE delivery
technique, duration of follow-up, procedure-associated complica-
tions, and outcomes based on the Response Evaluation Criteria in
Solid Tumours (RECIST), criteria defined by the European Asso-
ciation for the Study of the Liver (EASL) or other bases.
Results
Histology
Of the eight publications reviewed, five referred to primary
hepatic carcinoma (four HCC,15,16,19,22 one CCA21). The remaining
three studies treated metastatic liver disease and included two on
metastatic colorectal cancer,17,18 and one on metastatic neuroen-
docrine disease.23
Of the abstracts, 14 provided response rates of HCC to treat-
ment with DEB-TACE (Table 2). Three investigated the use of
DEB-TACE in the treatment of metastatic colorectal carcinoma
(MCRC) and provided response rates. A total of 19 provided data
on safety and mortality associated with DEB-TACE in histologies
including HCC, CCA, MCRC, metastatic neuroendocrine (MNE)
disease, melanoma, and, in one study, metastases of various
origins.
Patient selection
Patient selection among publications varied according to tumour
histology. Inclusion and exclusion criteria were reviewed in an
attempt to identify unifying themes. Some publications were more
thorough in defining these criteria than others.15,23 Abstracts were
reviewed in the same fashion, but were found to provide informa-
tion even less consistently than publications.
Embolization procedure
Chemotherapeutic options for DEB-TACE include doxorubicin,
epirubicin and irinotecan, depending on the type of malignancy.
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A DC Bead™ loaded with doxorubicin (Adriblastin® and Adria-
mycin® powder) has a target dose of 75 mg/2 ml and total
doses should not exceed 150 mg/m2.15 DC Bead™ loaded with
epirubicin (Farmorubicin® 50 mg powder) has a target dose
75 mg/2 ml. DC Bead™ loaded with irinotecan (Campto®
injection solution [100 mg/5 ml]) has a target dose of 100 mg/
2 ml.17,18,21
Patients undergo intra-arterial DEB administration using
angiography. The catheter is placed as selectively as possible in
order to isolate the blood supply to the malignancy and achieve
localized chemotherapy. Selective hepatic embolization involves
embolization of the right or left hepatic arteries separately as they
branch from the proper hepatic artery. Superselective or highly
selective embolization involves embolization of branches leading
off from the hepatic arteries, preferably the lesion itself or its
feeding branches. The size of DEB is chosen according to the
particular study, usually with smaller particles (100–300 mm or
300–500 mm) being selected first, followed by larger particles
(500–700 mm).
Multiple embolizations may be given to a quantity of three or
four per 6-month period.15,22 Patients receiving embolization are
monitored closely after each procedure in case hepatic failure
develops or any other criteria become apparent that would
exclude them from further therapy. Dose of chemotherapy used
Potentially relevant publications 
identified and screened for retrieval 
n = 500 
Publications retrieved for more 
detailed evaluation  
n = 8
RCTs excluded n = 482
List reasons n = Did not use DC 
Bead
Potentially appropriate publications 
to be included in the review 
n = 8
Publication included in review 
n = 8 
RCTs with usable information, by 
outcome
n = 8
Abstracts retrieved for more 
detailed evaluation  
n = 19
Abstracts appropriate for review
n = 19 
Figure 1 QUORUM algorithm of review of the DC Bead™ publications and abstracts. RCT, randomized controlled trial
Table 1 Data for published studies reviewed (n = 8)
Author(s) Date Histology Patients, n Chemotherapy
agent
Response rate
reported
Complications
reported
Survival
reported
Malagari et al. Nov 2007 HCC 71 Doxorubicin Yes Yes Yes
Poon et al. Sep 2007 HCC 35 Doxorubicin Yes Yes Yes
Aliberti et al. Oct 2006 MCRC 10 Irinotecan Yes Yes Yes
Fiorentini et al. Nov 2007 MCRC 20 Irinotecan Yes Yes Yes
Aliberti et al. July 2008 CAC 20 Doxorubicin Yes Yes Yes
Varela et al. March 2007 HCC 27 Doxorubicin Yes Yes Yes
de Baere et al. June 2008 NE 20 Doxorubicin Yes Yes Yes
Kettenbach et al. Jan 2007 HCC 30 Doxorubicin Yes Yes Yes
HCC, hepatocellular carcinoma; MCRC, metastatic colorectal cancer; CAC, cholangiocarcinoma; NE, neuroendocrine disease
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may be decreased in individuals with elevated bilirubin. A
maximum lifetime dose of 450 mg/m2 doxorubicin is
recommended.
Calculation of tumour response
Tumour response was calculated using either contrast-enhanced
spiral computed tomography (CT) or magnetic resonance
imaging (MRI) with quantification of tumour response according
to either RECIST or EASL criteria.16 Treatment response using
RECIST response criteria was categorized as complete response
(CR) or partial response (PR). Complete response is defined by
the disappearance of measurable disease, or the absence of arterial
phase contrast enhancement as measured by CT, persisting for4
weeks without the appearance of new measurable lesions. Partial
response is defined as a 30% reduction in the sum of the prod-
ucts of the greatest diameter (length) and the greatest perpendi-
cular diameter (width) of all measurable lesions compared with
baseline, and no appearance of new measurable lesions. Stable
disease (SD) represents cases in which neither PR nor progressive
disease (PD) criteria are met, taking as reference the smallest sum
of the greatest diameter recorded since the commencement of
treatment. Progressive disease (PD) is defined by the occurrence
of one of the following conditions: (i) the sum of the cross
products of all measurable lesions, including new lesions,
increases by >50% compared with the nadir, or (ii) new measur-
able lesions occur in any part of the body outside the liver.24
Treatment response assessment using EASL criteria repre-
sented a measure of local tumour response based on tumour
progression with respect to change in necrosis. The greatest
diameter of viable tumour against greatest total tumour dia-
meter is measured and initial measurements are compared with
those after each chemoembolization treatment.25 New tumour
development in a previously treated area is not considered as
progression.
Stage and resectability
Tumours were categorized as being unresectable in eight of eight
publications (Table 1). One additional publication not included
investigated outcomes in HCC after initial RFA failure followed
by DEB-TACE.20 Patients selected for studies treating HCC were
classified as Child–Pugh class A only in three of four studies.16,19,22
The remaining study treated both Child–Pugh classes A and B
patients.15
All publications required patients to have an HCC diagnosis
confirmed by either clinical criteria (EASL) or biopsy. Patients did
not have HCC that was suitable for resection, liver transplantation
Table 2 Data for abstracts reviewed (n = 19)
Author(s) Meeting/date Histology Patients, n Chemotherapy
agent
Response
rate reported
Complications
reported
Survival
reported
Slanic et al. WCIO 2008 Best
of ASCO
HCC 9 N/A No Yes Yes
Vit et al. CIRSE 2007 HCC 33 Doxorubicin Yes Yes Yes
Chamsuddin et al. SIR 2008 HCC 40 Doxorubicin Yes No Yes
Nicolini et al. SIR 2008 HCC 16 Epirubicin Yes Yes Yes
Reyes et al. SIR 2008 HCC 20 Doxorubicin Yes Yes Yes
Reyes et al. CIRSE 2007 HCC 10 Doxorubicin Yes Yes Yes
Fiorentini et al. ASCO GI 2008 MM 9 Irinotecan No Yes Yes
Bargellini et al. CIRSE 2007 HCC 61 Epirubicin Yes No No
Kamel et al. SIR 2007 HCC 10 Doxorubicin No Yes Yes
Lammer et al. SIR 2005 HCC 11 Doxorubicin Yes No No
Lammer et al. CIRSE 2005 HCC 21 Doxorubicin Yes Yes Yes
Wiskirchen et al. SIR 2007 HCC 20 Epirubicin No Yes Yes
Hong et al. SIR 2008 HCC 190 Cisplatin Doxorubicin
Mitomycin C
No Yes Yes
Bezzi et al. CIRSE 2007 HCC 25 Doxorubicin No Yes Yes
Grosso et al. SIR 2008 HCC 50 Doxorubicin Epirubicin Yes Yes Yes
Yamamoto et al. ASCO GI 2007 HCC 20 Doxorubicin Yes No Yes
Kalva et al. SIR 2008 HCC 23 Doxorubicin Yes Yes Yes
de Baere et al. CIRSE 2007 Multiple 10 Irinotecan Doxorubicin No No No
Nguyen et al. WCIO 2008 & Best of
ASCO
HCC 4 Doxorubicin No No Yes
N/A, not available; WCIO, World Congress International Oncology; ASCO, American Society of Clinical Oncology; CIRSE, Cardiovascular and
Interventional Radiological Society of Europe; SIR, Society of International Oncology; ASCO GI, ASCO gastrointestinal; HCC, hepatocellular
carcinoma; MCRC, metastatic colorectal cancer; CAC, cholangiocarcinoma; NE, neuroendocrine disease
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or percutaneous ablation according to Barcelona Clinic Liver
Cancer (BCLC) staging,with the exception of one study19 (Table 3).
Patient exclusion criteria for the treatment of HCC in all pub-
lications included bilirubin levels >3 mg/dl, advanced tumoral
disease including vascular invasion and extrahepatic spread, con-
traindications to doxorubicin administration (white blood cell
count >3000 cells/mm3, neutrophils <1500 cells/mm3, cardiac
ejection fraction <50%), any contraindication to hepatic embo-
lization procedures (portosystemic shunts, hepatofugal blood
flow, impaired coagulation [platelet count <50 000/mm3, pro-
thrombin activity <50%]), renal insufficiency or failure (serum
creatinine >2 mg/dl), and severe atheromatosis.
Inclusion criteria for the treatment of MCRC included histo-
logically confirmed colorectal carcinoma with metastatic disease
confirmed by CT, Karnofsky performance status 60% or World
Health Organization (WHO) criteria performance status of 0–2.
Patients were required to have undergone previous chemo-
therapy discontinued 4 weeks prior to beginning the study and
to have no signs of infection or ascites (Table 3). Other criteria
varied between studies and included normal metabolic and
laboratory testing, life expectancy of 3 months and age <85
years.
Exclusion for MCRC included any history of inflammatory
bowel disease or previous extensive bowel resection, signs of
cardiac disease, or renal, bone marrow, pulmonary or central
nervous system metastases. Uncontrollable infections, as well as
other types of cancer (except treated in situ cervical, basal cell
carcinoma or squamous cell carcinoma) were excluding factors.
One study excluded patients with prior treatment with topoi-
somerase inhibitors.
Patients with CCA included in a single study by Aliberti et al.
were required to have a Karnofsky performance score >60%,
tumour substitution <60% and normal liver function levels up to
twice the upper limit of normal.21 Other than failure to meet the
aforementioned inclusion criteria, no exclusion criteria were
specified (Table 3).
Inclusion criteria for a single study evaluating treatment of
MNE disease by de Baere et al. required patients to be aged 18–75
years, and to have histologically proven disease with two or fewer
mitoses per high-powered field, and proven progressive disease on
two subsequent imaging studies according to RECIST criteria,
including an increase in the size of known liver metastases
(Table 3).23 Additional criteria included serum bilirubin less than
twice the upper limit of normal, serum aspartate aminotrans-
ferase (AST) and alanine aminotransferase (ALT) levels less than
three times the upper limit of normal, serum creatinine levels
<120 mol/l, prothrombin time lower than 1.5 IU and a platelet
count of >106/mm3.
Exclusion criteria in this study excluded candidates
with any resectable disease, predominant extrahepatic disease,
biliary tract dilation, bilioenteric anastomosis or biliary stent
crossing the ampulla of Vater, and previous treatment with
TACE.
Delivery technique
Doxorubicin was the chemotherapeutic agent used in the treat-
ment of all HCC publications and most abstracts (Tables 1 and 2).
Doxorubicin doses commenced with delivery of 25 mg/m2 and
ranged up to a maximum dose of 150 mg/m2. Irinotecan was used
in treating those with MCRC. Irinotecan was administered at
doses of 100 mg per TACE procedure. Drug-eluting bead TACE
was administered using angiography to determine the catheter
placement and to embolize as selectively as possible. Bead size
varied from 100–300 mm to 500–700 mm across studies, depend-
ing on the size of the vessel embolized and patency following
initial embolization.
Response rates
Using EASL criteria, publications following the treatment of HCC
reported overall response (OR) rates of 65% (66/101; CR 5%, PR
60%) at 1 month, 71% (65/91; CR 9%, CR 63%) at 4 months, 75%
(61/81; CR 14%, PR 62%) at 6–7 months and 88% (7/8; CR 25%,
PR 63%) at 10 months (Table 4). Stable disease rates were
reported as 27% (27/101) at 1 month, 12% (11/91) at 4 months,
12% (10/81) at 6–7 months and 13% (1/8) at 10 months. Progres-
sive disease rates were reported at 7% (7/101) at 1 month, 16%
(15/91) at 4 months, 9% (7/81) at 6–7 months and 0% (0/8) at 10
months (Table 4). An investigation by Lencioni et al. involving
combination therapy of RFA with DEB-TACE using EASL criteria
reported an OR of 75% (CR 50%, PR 25%) in 20 patients with
HCC at 12 months, as well as SD and PD rates of 0% and 25%,
respectively.20
Using RECIST criteria, publications treating HCC reported OR
rates of 50% (15/30) at 1 month (CR 0%, PR 50%, SD 27%, PD
23%). Overall response at 4 months was 36% (10/28; CR 0%, PR
36%, SD 18%, PD 46%). Overall response at 6 months was 42%
(24/57; CR 14%, PR 28%, SD 38%, PD 20%). A single study
reporting response rates at 6 months did not account for five of 30
(17%) patients involved in the study; therefore those patients were
not included in response rate calculations.
Among those investigations of HCC using RECIST criteria, two
abstracts reported OR rates of 9% and 19% at 1 month (Kalva
et al.26; Reyes et al.27; Tables 2 and 4). The abstract with 19% OR
(Reyes et al.) also reported an SD rate of 71% and a PD rate of
10% in 23 patients. Two abstracts reported response rates at 2 and
3 months with ORs of 29% (6/21) and 50%, respectively (Kalva
et al.; Reyes et al.). The abstract reporting 3-month responses had
an SD rate of 43% and a PD rate of 7%. One publication19 and one
abstract reporting response rates at 6 months had OR rates of 44%
and 52% (CR 0%, PR 52%), respectively. Malagari reported an OR
of 62% in 62 patients at the 2-year follow-up, 29% of whom
exhibited SD.15
Aliberti et al. studied response rates in CCA at 3 months using
RECIST criteria and found an OR rate of 100% (11/11; CR 9%, PR
82%, SD 0%, PD 0%) (Table 5).21 A single patient in this study was
unaccounted for and therefore excluded from statistics. Fiorentini
et al. evaluated MCRC in a single publication using RECIST
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criteria and reported an OR rate at 1 month of 80% (16/20).18
Another publication by Aliberti et al. studied response rates in
MCRC at 1 month and reported an OR of 100% (10/10), but did
not clarify the criteria used.17
De Baere et al. reported response rates in MNE disease using
RECIST criteria at 1 and 3 months.23 Overall response rates were
50% (10/20) at 1 month (CR 0%, PR 50%, SD 45%, PD 5%) and
80% (16/20) at 3 months (CR 0%, PR 80%, SD 15%, PD 5%).23
Safety
The various publications reported complications according to two
methods: by procedure and by patient (Table 1). The most
common procedure-associated complications included fever
(85% of patients, 46% of procedures), nausea and vomiting (93%
of patients, 52% of procedures), abdominal pain (80% of patients,
44% of procedures) and liver abscess (2% of patients, 1% of
procedures). Rather than describing individual symptoms, two
studies reported post-embolic syndrome (PES), consisting of
fever, abdominal pain and nausea or vomiting, as occurring in
82% (75/91) of patients. Six of nine studies reported length of
hospital stay, which averaged 2.3 days per procedure. Mortality
was reported to occur in 11 in 533 (2%) procedures, or in 11 in
253 (5%) patients. Causes of mortality included myocardial inf-
arction (n = 3), progressive liver disease (n = 5), pulmonary embo-
lism (n = 1), postoperative sepsis (n = 1) and liver failure (n = 1).
Additional complications included mild asthenia (n = 8), alopecia
(n = 7), acute cholecystitis (n = 2), hepatic infarction (n = 2),
pulmonary effusion (n = 1), gastric ulcer haemorrhage (n = 1),
Table 4 Response rates according to criteria and follow-up in hepatocellular carcinoma
Author(s) Criteria Follow-up, months Patients, n OR CR PR SD PD N/A
Reyes et al. 2008 EASL 1 22 14 (64%) N/A N/A N/A N/A 8 (36%)
Bargellini et al. 2007 EASL 1 30 87% 53% 34% N/A N/A 13%
Reyes et al. 2008 EASL 2 21 16 (76%) N/A N/A N/A N/A 5 (24%)
Varela et al. 2007 EASL 6 20 78% 39% 61% N/A N/A 0 (0%)
Vit et al. 2007 EASL 6 33 93% 70% 23% N/A N/A 7%
Bargellini et al. 2007 EASL 6 23 N/A N/A N/A N/A 7 (30%) 23 (70%)
Reyes et al. 2007 EASL 7 10 10 (100%) NR NR 0 (0%) 0 (0%) 0 (0%)
Nicolini et al. 2008 EASL 8 9 85% 71% 14% N/A 14% 1%
Kalva et al. 2008 RECIST 1 23 19% N/A N/A 71% 10% 0 (0%)
Reyes et al. 2008 RECIST 1 22 2 (9%) N/A N/A N/A N/A 20 (91%)
Kalva et al. 2008 RECIST 3 14 50% N/A N/A 43% 7% 0 (0%)
Reyes et al. 2008 RECIST 2 21 6 (29%) N/A N/A N/A N/A 15 (61%)
Varela et al. 2007 RECIST 6 20 52% 0% 52% N/A N/A 48%
Kalva et al. 2008 RECIST 6 9 44% N/A N/A 56% 0% 0 (0%)
Reyes et al. 2007 RECIST 7 10 25% 0% 25% 75% 0% 0 (0%)
Malagari et al. 2007 RECIST 24 62 62% N/A N/A 29% N/A 9%
Grosso et al. 2008 Unknown 1 50 43 (86%) 27 (54%) 16 (32%) 0 (0%) 7 (14%) 0 (0%)
Chamsuddin et al. 2008 Unknown 2 29 86% 76% 10% 7% 7% 0 (0%)
Lammer 2005 Unknown 3 11 8 (73%) 3 (27%) 5 (45%) 3 (27%) 0 (0%) 0 (0%)
Grosso et al. 2008 Unknown 6 35 16 (46%) 10 (29%) 6 (17%) 0 (0%) 5 (14%) 14 (40%)
Lammer 2005 Unknown 6 21 15 (71%) 9 (43%) 6 (28%) 2 (10%) 3 (14%) 1 (5%)
Yamomoto et al. 2007 Unknown 6 23 15 (65%) 11 (48%) 4 (17%) 6 (26%) N/A 2 (9%)
OR, overall response; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; N/A, not available; EASL, European
Association for the Study of the Liver; RECIST, Response Evaluation Criteria in Solid Tumours
Table 5 Response rates according to criteria and follow-up in metastatic colorectal cancer
Author(s) Criteria Follow-up,
months
Patients, n OR CR PR SD PD N/A
Aliberti et al. 2006 RECIST 1 20 90% N/A N/A N/A N/A 10%
Fiorentini et al. 2007 RECIST 9.2 18 80% N/A N/A N/A N/A 20%
Fiorentini et al. 2008 RECIST N/A 20 90% N/A N/A N/A N/A 10%
OR, overall response; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; N/A, not available; EASL, European
Association for the Study of the Liver; RECIST, Response Evaluation Criteria in Solid Tumours
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variceal bleed (n = 1), spontaneous bacterial peritonitis (n = 1),
rash (n = 1) and pancreatitis (n = 1). A transient increase in liver
function enzymes was reported in most studies.
Abstracts were less consistent in reporting complications. Fever
was reported as a common side-effect in 77% (30/39) of studies
and as a frequent complication in five other studies. Nausea and
vomiting was reported as a common side-effect in 70% (21/30) of
studies and as a frequent complication in four other studies. Right
upper quadrant pain was reported in 53% (40/75) of patients and
was frequent in four additional studies. Post-embolic syndrome
was reported in place of the aforementioned symptoms in 66%
(80/122) of studies and occurred in some patients in two addi-
tional studies, although numbers were not quantified. One study
reported hospital stay as averaging 1.8 days. Mortality was
reported as occurring in 36 of 698 patients (5%). Causes included
progressive disease (n = 14), hepatic failure (n = 3), postoperative
sepsis (n = 2, cardiovascular disease (n = 2), myocardial infarction
(n = 1), pulmonary embolism (n = 1), head trauma (n = 1), death
following gastric ulcer repair (n = 1) and were not specified (n =
11). Additional complications included hepatic failure (n = 7),
pancreatitis (n = 5), cholecystitis (n = 3), gastritis (n = 2), enteritis
(n = 2, of which one was a hemorrhagic duodenitis), acute renal
failure (n = 1), hepatic rupture (n = 1), hepatic infarction (n = 1)
and fistula formation between the duodenum and tumour (n = 1).
Other complications included skin rash, decreased appetite,
decreased libido, fatigue, alopecia, asthenia, leucocytopenia,
anaemia, thrombocytopenia, neutropenia, hypoalbuminaemia
and transiently increased liver function enzymes.
Discussion
We do not yet have a standardized method for reporting data on
the utilization of various therapies in hepatic disease, including
Yttrium-90, transarterial embolization, TACE and DEB-TACE.
This makes it difficult to compare current results because of the
variability across studies, such as in the number of cycles of DEB
administered, total doses of chemotherapy given to patients, dif-
ferences in inclusion and exclusion criteria, and differences in the
criteria used to report responses. The method of data reporting in
publications and abstracts did not allow for comparisons of indi-
vidual patient response by number of treatments received.
However, despite these inconsistencies, considerable response to
therapy was evident in studies that followed patients within the
first year of treatment. Certain trends can be seen clearly, such as
an increase in overall response in patients who received additional
cycles of DEB-TACE and higher levels of chemotherapy. Patients
who did not respond adequately to initial therapy and who did
not have significant toxicity were candidates for additional treat-
ments until either adequate response was achieved or they
received the maximal dose of chemotherapy. It will be helpful to
correlate these factors with response criteria in future studies in
order to determine whether overall response is significantly
dependent on multiple treatments.
The difference in response reported by EASL criteria vs. that
reported by RECIST criteria was also notable. Among publica-
tions reporting both criteria (i.e. Poon et al.16), using EASL criteria
gave larger tumour response rates than did RECIST criteria. The
latter criteria determine measurements based on the extent of
measurable disease and the presence of arterial phase on CT, but
do not take the extent of necrosis into consideration. However,
EASL-based criteria contrast with RECIST criteria because they
include measurement of tumour necrosis as well as viable tumour
in order to determine the extent of response. Although results
based on different criteria varied, longterm response and survival
rates should not vary because DEB-TACE administration was
similar independent of evaluation criteria. Those studies report-
ing response rates by unknown criteria could not be accurately
compared with EASL- or RECIST-based studies, but still provided
valuable information concerning overall tumour response. Data
from abstracts, although helpful in reporting initial response rates
and procedure-related safety, should not be compared with pub-
lished data until the studies to which the abstracts pertain have
been finalized. Information was not consistently reported among
abstracts, with the result that some values obtained, specifically
complication rates, are less valuable because of the lack of patient
numbers.
Short-term follow-up provided valuable information concern-
ing response rates. Although short-term evaluation indicates that
the procedure effectively embolizes and causes tumour necrosis,
continued follow-up is essential in order to determine the long-
term significance of DEB-TACE and its role as an alternative
therapy or palliative measure in treating patients with hepatic
malignancy. Some abstracts described ongoing studies investigat-
ing the use of DEB-TACE over an extended follow-up period, such
as a 2-year study by Malagari et al., which followed 62 patients.
Another abstract that might provide significant information refers
to a study by Hong et al., which followed 190 patients treated with
DEB-TACE for 1 year. Low rates of disease progression and
procedure-related mortality associated with current publications
are encouraging, but time will be a major factor in determining
overall benefit.
Drug-eluting bead TACE appears to be a relatively safe proce-
dure, with few longterm serious complications associated with its
administration. Although symptoms of PES, such as fever, nausea
or vomiting and abdominal pain appear to occur in most patients,
these symptoms are associated with short hospital stays averaging
2.3 days among publications, which is significantly lower than for
conventional TACE procedures. The most frequent major compli-
cation associated with this procedure was liver abscess, which
occurred in approximately 0.75–1.58% of publications and
approximately 0.29% of abstracts. Other complications were
infrequent, although some were quite severe. Overall mortality is
potentially lower than the reported values (2.06–4.74% in publi-
cations and 5.16% in abstracts) because reported mortality rates
included both procedure-related causes of death, such as sepsis
and hepatic failure, and death secondary to progressive disease,
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cardiovascular disease, pulmonary embolism and other causes.
Patients selected for these studies are predisposed to
co-morbidities as a result of their diminished hepatic function
and potentially other age- or lifestyle-related conditions, which
should be taken into consideration.
Use of DEB-TACE in current publications seems to be
restricted to patients with unresectable liver disease and reason-
able hepatic function (Child–Pugh classes A and B). Future pub-
lications are considering patients with more severe disease; for
example, two abstracts by Kalva et al. and Malagari et al. report
the inclusion of Child–Pugh class C patients. A study by Lencioni
et al. was the only publication to address the use of DEB-TACE as
combination therapy with RFA.20
At the 1-year follow-up, an OR of 75% using EASL criteria was
documented. Although no comparisons can be drawn because no
similar studies have been reported, several abstracts were of
similar design. Combination therapy may prove to be effective as
an alternative treatment in unresectable liver disease. Other inter-
esting uses of DEB-TACE mentioned in abstracts include as emer-
gent therapy for the purpose of embolizing ruptured tumours in
patients with HCC.
Conclusions
The current results show DEB-TACE to produce beneficial
tumour response and to have exceptionally low complication
rates. The technique has the potential to become an effective alter-
native therapy or palliative measure in the treatment of hepatic
malignancy, but both delivery and data collection must be stan-
dardized in order to clarify efficacy. It is a safe alternative in the
treatment of unresectable hepatic malignancy, but is unproven as
an adjunctive treatment to other standard therapies such as resec-
tion and RFA. Further investigation is essential to better define its
role as an adjunct in treating hepatic malignancy.
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